

OFFICIAL PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Case No. MBHB 00-1257-B)

FAX RECEIVED

In the Application of: Campbell, et al. )

Serial No. 10/005,064 )

Filed: December 4, 2001 )

Title: ABCA-1 Elevating Compounds )

Examiner: D. Rao

Group Art Unit: 1624

SEP 20 2002

GROUP 1600

CERTIFICATE OF FACSIMILE TRANSMISSION

FACSIMILE NO. 1-703-308-4556


(Total Number of Pages, including this sheet: 20)

Assistant Commissioner of Patents

Washington, D.C. 20222

Attn: Examiner D. Rao

The undersigned hereby certifies that this paper and every paper referred to therein as being enclosed is being transmitted by facsimile to the Assistant Commissioner of Patents, Washington, DC 20202, on September 20, 2002.

Date: September 20, 2002  
A. Blair Hughes  
Reg. No. 32,901

Enclosures: Petition for Extension of Time Under 37 CFR 1.1369(a) in duplicate and Amendment and Response Under 37 CFR 1.111 with Appendix A and Appendix B.

#61A  
9/25/02  
C. Dufes

PATENTS  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(00-1257-B)

Re Application of: Campbell et al. )  
Serial No. 10/005,064 )  
Filed: 12/04/2001 )  
Examiner: Deepak R. Rao  
Group Art Unit 1624

For: ABCA-1 ELEVATING COMPOUNDS

Assistant Commissioner of Patents  
Washington, D.C. 20231  
Sir:

**AMENDMENT AND RESPONSE UNDER 37 CFR 1.111**

The Examiner is respectfully requested to consider the following amendments and accompanying remarks, which are in response to the Office action mailed May 20, 2002. Reconsideration of the rejection of Claims 9, 28-38, 44 and 62 is requested in light of the following amendments and remarks, which are being filed within four months of the action. Applicants note that Claims 1-63 are pending in the Application, of which claims 14-27 and 48-61 are withdrawn from consideration, claims 9, 28-38, 44 and 62 are rejected, and claims 1-8, 10-13, 39-43, and 63 are objected to.

Please amend the above-captioned specification as follows:

**IN THE CLAIMS:**

Please amend the claims as follows:

Please cancel claims 2, 14-27, 37, and 48-61 from the application without prejudice.

1. (Once amended) A method of treating a disease state in a mammal that is alleviable by treatment with an agent capable of increasing ABCA-1 expression, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of the Formula I: